Form 4: Cidara Director's Options Cashed Out in Merck Merger

Cidara Therapeutics director Joshua Resnick's stock options were converted to cash following the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC through its wholly-owned subsidiary, Caymus Purchaser, Inc.
• The merger was completed on January 7, 2026, following a tender offer to acquire all outstanding shares of Cidara's common and Series A preferred stock.
• Cidara Therapeutics, Inc. now operates as a wholly-owned subsidiary of Merck.
• Director Joshua Resnick's outstanding stock options became fully vested and were cancelled, converting into a cash payment.
• The cash payment for each option was calculated as the total number of shares subject to the option multiplied by the difference between the merger price ($221.50 per Common Share) and the option's exercise price.
• Resnick disclaims beneficial ownership of the options and underlying common stock, as they are held for the benefit of RA Capital Healthcare Fund, L.P., with net proceeds to be turned over to RA Capital Management, L.P.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of Cidara Therapeutics' acquisition by Merck, resulting in the cash-out of director stock options at a significant premium. This is a positive outcome for Cidara's equity holders.

Positives

• The merger completion indicates a successful exit for Cidara Therapeutics' shareholders and option holders.
• Outstanding stock options held by Director Joshua Resnick were fully vested and cashed out at a significant premium over their exercise prices, specifically $221.50 per share compared to exercise prices of $26.62 and $21.31.

Negatives

• Cidara Therapeutics, Inc. has ceased to be an independent publicly traded company.
• Former shareholders no longer have direct equity exposure to Cidara's future growth as a standalone entity.

Future Outlook

Cidara Therapeutics, Inc. has become a wholly-owned subsidiary of Merck Sharp & Dohme LLC. Its future operations and strategic direction will be integrated within Merck's broader corporate structure. No independent future outlook for Cidara is provided.

Management Comments

• Joshua Resnick disclaims beneficial ownership of the option and underlying common stock, as he holds the option for the benefit of RA Capital Healthcare Fund, L.P. and is obligated to turn over any net cash or stock received to RA Capital Management, L.P.

Industry Context

This transaction reflects a broader trend of consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to expand their pipelines and intellectual property. Merck's acquisition of Cidara suggests a strategic move to integrate Cidara's assets and capabilities into its own portfolio, potentially enhancing its market position in relevant therapeutic areas.

Comparison to Industry Standards

• The acquisition price of $221.50 per common share for Cidara Therapeutics, Inc. represents a substantial premium over the reported option exercise prices ($26.62 and $21.31), indicating a strong valuation for Cidara's equity at the time of the merger.
• Without specific details on Cidara's pipeline, financial performance, or market capitalization prior to the merger, a direct comparison to specific M&A transactions involving comparable companies like BioNTech's acquisition of InstaDeep or Pfizer's acquisition of Seagen is not possible from this filing alone.

Stakeholder Impact

• Shareholders: Received cash for their shares, ending their direct equity ownership in Cidara Therapeutics.
• Option Holders: Received cash for their vested options at a premium, realizing a significant gain.
• Employees: Cidara employees are now part of Merck, subject to Merck's corporate policies and structure.
• Cidara Therapeutics as an entity: Ceased to be an independent public company, now operates as a subsidiary of Merck.

Next Steps

• Cidara Therapeutics, Inc. will operate as a wholly-owned subsidiary of Merck Sharp & Dohme LLC.
• Integration of Cidara's operations and assets into Merck's corporate structure.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, Joshua Resnick, RA Capital